DCTY-1102

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameDCTY-1102
Drug Alias NameDCTY1102DCTY-1102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionKRAS G12D inhibitors
TargetsKRAS G12D
Therapy Area/IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing DCTY Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing DCTY Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A